Evidence map›Paper›PMID 33772330›Full record

Observational studyArchives of gynecology and obstetrics2021

Vaginal treatment with lactic acid gel delays relapses in recurrent urinary tract infections: results from an open, multicentre observational study.

Ruth Diebold, Bettina Schopf, Holger Stammer, Werner Mendling

Erratum issuedOpen access · hybridAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Archives of gynecology and obstetrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Vaginal Microbiome in Reproductive Medicine.Diagnostics (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ruth DieboldDr. Kade Pharmazeutische Fabrik GmbH, Berlin, Germany. ruth.diebold@kade.de.ORCID http://orcid.org/0000-0002-2007-6040
Bettina SchopfPharmalog Institut für klinische Forschung GmbH, Ismaning, Germany.
Holger StammerPharmalog Institut für klinische Forschung GmbH, Ismaning, Germany.
Werner MendlingGerman Centre for Infections in Obstetrics and Gynecology, Wuppertal, Germany.
Pharmalog (Germany) · DEDr. Kade Pharmazeutische Fabrik (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe main objective of this open, prospective, multicentre, observational study is to investigate the relapse rate and tolerability of lactic acid gels in adult female patients with recurrent urinary tract infections during routine practice.

methodsData were collected from patients undergoing intermittent short courses of intravaginal treatment with lactic acid gel for prevention of recurrent urinary tract infections. The observation period for individual patients was 4 months, aimed at covering four short courses of intravaginal treatment. Data on UTI relapses, tolerability, handling and satisfaction with the treatment were collected via patient diaries and physician assessments and comprised any adverse events (AEs).

resultsIn total, 72 patients were treated. During the last 12 months prior to the study, patients had on average 4.0 UTIs. In the 4 months after commencing treatment, 63.5% of patients had no recurrence of UTI symptoms. Overall efficacy was rated by physicians as 'excellent/good' for 96.7% of patients. The patients' overall acceptance of local treatment was high with 94.1% being '(very) satisfied'. Similarly, handling was rated as '(very) easy' by 94.2% of patients. The tolerability was assessed as 'highly tolerable/tolerable' by over 98% of patients and physicians alike. Safety analyses reported six AEs of mild intensity, all of which had resolved by the end of the study.

conclusionTreatment with lactic acid gel may increase resilience against uropathogens, possibly preventing the need for antibiotic prevention of recurrent urinary tract infections. Treatment was positively assessed by the patients. The physician assessments corroborate these findings. TRIAL REGISTRATION NUMBER AND DATE OF REGISTRATION: DRKS00016760, 18.02.2019.

Indexed as

AdolescentAdultAgedAnti-Bacterial AgentsFemaleGelsHumansLactic AcidMiddle AgedProspective StudiesRecurrenceSecondary PreventionUrinary Tract InfectionsYoung AdultAnti-Bacterial AgentsGelsLactic AcidLactic acid gelPreventive treatmentRelapse reductionUrinary tract infectionUropathogen

Identifiers

PMID33772330
PMCPMC8277613
OpenAlexW3138372856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.